RxDoctor Payments Data

Krystal Shilo

Gerontology · Houston, TXNPI 1477222107

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.0% of the total across 371 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 7.4% — the pattern of someone who eats at a lot of different presentations. Among gerontology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,412in general payments, 2019–2025

Across 371 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$623
  • Pfizer$548
  • AbbVie$458
  • Tempus AI, Inc$438
  • Jazz Pharmaceuticals Inc.$386
  • Novartis$373
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$7,82293%
  • Education$5907%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)26$623
Pfizer29$548
AbbVie13$458
Tempus AI, Inc25$438
Jazz Pharmaceuticals Inc.7$386
Novartis18$373
Astellas Pharma US Inc13$353
E.r. Squibb & Sons, L.L.C.21$351
Bristol Myers Squibb14$335
Seagen Inc.8$329
AstraZeneca(2 entities)15$324
Daiichi Sankyo Inc.14$303
Bayer7$224
Merck10$222
Sanofi10$210
Array Biopharma Inc8$173
Tersera Therapeutics LLC7$173
Rigel Pharmaceuticals, Inc.8$171
Beone Medicines USA, Inc.6$163
Lilly USA, LLC7$153
Eisai Inc.6$126
Pharmaessentia USA Corporation6$123
Sobi, Inc5$99
Pharmacosmos Therapeutics Inc.4$88
Tactile Systems Technology Inc5$82
Fennec Pharmaceuticals, Inc.6$80
EMD Serono, Inc.4$79
Deciphera Pharmaceuticals Inc.3$78
GSK3$73
Amgen3$69
Ipsen Biopharmaceuticals, Inc3$69
Springworks Therapeutics, Inc.3$69
Taiho Oncology, Inc.3$67
Incyte Corporation4$64
Morphosys, US Inc.3$59
AVEO Pharmaceuticals, Inc.3$57
Mirati Therapeutics, Inc.3$56
Pharmacyclics LLC, An Abbvie Company2$51
Blueprint Medicines Corporation2$50
Stemline Therapeutics Inc.2$45
Regeneron Healthcare Solutions, Inc.2$44
Servier Pharmaceuticals LLC2$42
Legend Biotech USA Inc.2$40
Puma Biotechnology, Inc.2$38
Kyowa Kirin, Inc.2$36
Genentech USA, Inc.2$33
Adaptive Biotechnologies Corporation2$32
Iovance Biotherapeutics, Inc.1$31
Beigene USA, Inc.1$28
Invivyd Inc1$25
Apellis Pharmaceuticals, Inc.1$23
Geron Corporation1$22
Dendreon Pharmaceuticals LLC1$21
Sumitomo Pharma America, Inc.1$21
Tolmar Pharmaceuticals, Inc.1$20
CTI Biopharma Corp.1$20
Genmab U.S., Inc.1$19
ADC Therapeutics America, Inc.1$18
Caris MPI, Inc.1$16
Gilead1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,412 in reported general payments places this provider in the 95th percentile of 653 gerontology providers in Texas.

See all gerontology providers in Texas

Medicare billing

Part B allowed, 2024
$53,199
Medicare patients
197
Services billed
1,223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide19$249,047
PromactaEltrombopag Olamine12$177,747
EliquisApixaban66$45,608
XareltoRivaroxaban29$30,408
Abiraterone Acetate23$2,709
Enoxaparin Sodium15$2,108
Megestrol Acetate24$1,414
Letrozole47$1,051
Ondansetron OdtOndansetron37$384
Lidocaine-PrilocaineLidocaine/Prilocaine19$297
Potassium Chloride21$260
Dexamethasone34$228
Anastrozole21$203
Mirtazapine11$162
Prednisone19$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$335$249,04719 claims
NovartisPromacta$373$177,74712 claims
PfizerEliquis$548$45,60866 claims
Johnson & JohnsonXarelto$623$30,40829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 gerontology providers in Texas.

Other gerontology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →